Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | FNTA | P49354 | 1/20 | 0.48 |
| ▸ | FNTB | P49356 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL47278 | 1.00 | MMP8 (0.53) | MMP8KMT2AEGFRSRCCYP1A2 | |
| SCHEMBL1697377 | 1.00 | MMP8 (0.53) | MMP8KMT2AEGFRSRCCYP1A2 | |
| SCHEMBL18952189 | 0.86 | SPHK1 (0.62) | MMP8KMT2AEGFRSRCCYP1A2 | |
| SCHEMBL7413310 | 0.86 | ALPI (0.61) | MMP8KMT2AEGFRSRCMME | |
| SCHEMBL3114367 | 0.86 | ALPI (0.61) | MMP8KMT2AEGFRSRCMME | |
| SCHEMBL12240253 | 0.84 | KMT2A (0.55) | MMP8KMT2AEGFRSRCMME | |
| SCHEMBL2742291 | 0.84 | KMT2A (0.55) | MMP8KMT2AEGFRSRCMME | |
| SCHEMBL20569813 | 0.84 | TPSAB1 (0.58) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL16289699 | 0.84 | MMP2 (0.68) | MMP8KMT2AEGFRSRCCYP1A2 | |
| Hydrochloric Acid SCHEMBL3385081 | 0.84 | MMP8 (0.59) | MMP8KMT2AEGFRSRCMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106543018-A | The method for preparing scheme for lacosamide | 迪比斯实验股份有限公司 | 2017-03-29 | — | — | CN | disclosed |
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-6114534-A | REACTING A KETONE DERIVATIVE OF CARBAMOYL SUBSTITUTED HETEROCYCLE WITH PHOSPHORANE, FOLLOWED BY ACIDIFICATION TO FORM AN ANTICOAGULANT | ELI LILLY AND COMPANY (US) | 2000-09-05 | — | — | US | disclosed |
| US-6075147-A | OMEGA-PHENYL-OMEGA-(3-PYRIDYL)-OMEGA-ALKENOIC ACID DERIVATIVES BEARING A CARBAMOYL SUBSTITUTED OXAZOLYL OR OXAZOLINYL GROUP ON THE PHENYL RING IS USEFUL FOR THROMBOXANE RECEPTOR ANTAGONSIM OR THROMBOXANE SYNTHASE INHIBITOR | ELI LILLY AND COMPANY (US) | 2000-06-13 | — | — | US | disclosed |
| US-6031095-A | Intermediates in the preparation of substituted alkenoic acids | ELI LILLY AND COMPANY (US) | 2000-02-29 | — | — | US | disclosed |
| US-5990308-A | Intermediates in the preparation of substituted alkenoic acids | ELI LILLY AND COMPANY (US) | 1999-11-23 | — | — | US | disclosed |
| US-5849766-A | Carbamoyl substituted heterocycles | ELI LILLY AND COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| US-5849922-A | Preparation of substituted alkenoic acids | ELI LILLY AND COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0816361-A2 | Preparation of substituted alkenoic acids | ELI LILLY AND COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0811621-A2 | Carbamoyl substituted oxazoles as thromboxane receptor antagonists | ELI LILLY AND COMPANY (US) | 1997-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | TAOK1, TAOK3, MAP3K6 | MMP8 1252/4885KMT2A 2240/4885EGFR 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.